MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BP Bree Pate Olisti Co. Wealth LLC | 100 | $2,492 | $2,485 | -$7 | -0.28% |
| WCP Wealthcare Capital Partners LLC Wealthcare Capital Partners LLC | 18,375 | $456,986 | $457,170 | $184 | 0.04% |
| ARCA Exchange | US Country |
This investment fund focuses on maximizing returns through a strategic approach to investing in U.S. dollar-denominated tax-exempt variable rate demand obligations (VRDOs). By committing at least 80% of its total assets into the components of the underlying index, the fund aims to closely track the performance of these VRDOs. These financial instruments are primarily issued by U.S. states, territories, and their political subdivisions, offering investors exposure to tax-exempt income opportunities. The distinguishing feature of these obligations lies in their interest rates, which are designed to reset at periodic intervals — daily, weekly, or monthly, thus providing a degree of liquidity and interest rate sensitivity that is attractive to certain investors.
This product targets investors seeking exposure to tax-exempt income through investments in variable rate demand obligations (VRDOs) issued by U.S. states and territories, and their political subdivisions. With interest rates that reset periodically, these securities offer the potential for income that is not only tax-exempt but also responsive to changing market conditions. Ideal for conservative investors with a focus on preserving capital while gaining tax advantages.